Added to YB: 2024-04-05
Pitch date: 2023-12-31
CSTL [bullish]
Castle Biosciences, Inc.
+56.4%
current return
Author Info
No bio for this author
Company Info
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Market Cap
$1.1B
Pitch Price
$21.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
-74.27
P/E
-56.02
EV/Sales
2.49
Sector
Health Care Providers and Services
Category
growth
Next Century Growth Investors Micro Cap Strategy New Position: Castle Biosciences, Inc.
CSTL: Medical diagnostics firm w/ skin & esophageal cancer + mental health tests. Prior concerns on M&A abated as skin cancer volumes grow & deals add value. Low penetration across markets signals continued growth. Valuation compressed but balance sheet supports expansion & 2025 cash flow breakeven target.
Read full article (1 min)